

# Mobileye Global Inc. (MBLY)

# More limited market share and premium multiple; downgrade to Neutral

**MBLY** 

12m Price Target: **\$17.00** 

Price: **\$16.88** 

Upside: 0.7%

We're lowering our rating on Mobileye (MBLY) shares to Neutral from Buy to better reflect the competitive landscape, risk to Street estimates (FactSet) in 2026/2027, and what we consider to be full valuation (with the stock trading near our unchanged \$17 price target). While we continue to believe that Mobileye has strong vision and autonomous vehicle technical capabilities, the number of companies planning to use Mobileye technology for their future advanced ADAS/AV programs has been more limited than we had expected (both in China and globally). Competition has generally included in-house efforts and competitor silicon/systems, although some OEMs are also considering licensing L4 from tech companies besides Mobileye (e.g. Tesla or Waymo). We do expect Mobileye to be a meaningful provider in the market, as evidenced by its traction with VW and to support AVs for the Uber/Lyft network, but at a more moderate level. While the AV/robotaxi market is building momentum, we expect overall market AV volumes to be relatively limited for the next two to three years in the US given our view that AVs will remain mostly/entirely for commercial applications over that timeframe (please see our companion report AVs: Framing profit pools in rideshare, trucking, and insurance as AVs move from concept to commercialization for details).

Our Buy recommendation on the stock was wrong. While Buy-rated since 11/21/2022, MBLY shares were down 38% vs. the S&P 500 up 52%. We attribute the weakness in MBLY shares to lower market share and less design wins than we had expected, and weaker auto industry conditions (due in part to tariffs).

### Design wins have been mixed

We believe that Mobileye has a strong position in the ADAS market, with >50% market share and exposure to the majority of top OEMs

Mark Delaney, CFA

+1(212)357-0535 | mark.delaney@gs.com Goldman Sachs & Co. LLC

### Will Bryant

+1(212)934-4705 | will.bryant@gs.com Goldman Sachs & Co. LLC

### Aman Gupta

+1(212)357-1549 | aman.s.gupta@gs.com Goldman Sachs & Co. LLC


**Key Data** 

Market cap: \$13.7bn Enterprise value: \$12.0bn 3m ADTV: \$53.8mn United States Americas Autos & Industrial Tech M&A Rank: 3

### **GS** Forecast

	12/24	12/25E	12/26E	12/27E
Revenue (\$ mn)	1,654.0	1,714.4	1,776.2	2,015.7
EBITDA (\$ mn)	(24.0)	(9.8)	39.3	128.9
EBIT (\$ mn)	(86.0)	(103.8)	(88.7)	0.9
EPS (\$)	(0.09)	(0.10)	(0.05)	0.05
P/E (X)	NM	NM	NM	NM
EV/EBITDA (X)	NM	NM	299.3	88.5
FCF yield (%)	1.7	2.1	2.6	2.9
Dividend yield (%)	0.0	0.0	0.0	0.0
Net debt/EBITDA (X)	-	-	(52.5)	(19.1)
	3/25	6/25E	9/25E	12/25E
FPS (\$)	(0.00)	0.01	(0.06)	(0.05)

## **GS Factor Profile**



MBLY relative to Americas Autos & Industrial Tech

Source: Company data, Goldman Sachs Research estimates. See disclosures for details.

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to <a href="https://www.gs.com/research/hedge.html">www.gs.com/research/hedge.html</a>. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.



## Mobileye Global Inc. (MBLY)

Rating since Jun 9, 2025


### Ratios & Valuation \_\_\_\_

	12/24	12/25E	12/26E	12/27E
P/E (X)	NM	NM	NM	NM
EV/EBITDA (X)	NM	NM	299.3	88.5
EV/sales (X)	10.2	7.0	6.6	5.7
FCF yield (%)	1.7	2.1	2.6	2.9
EV/DACF (X)	58.4	28.0	22.3	18.7
CROCI (%)	1.9	3.1	3.8	4.3
ROE (%)	(0.5)	(0.7)	(0.4)	0.3
Net debt/EBITDA (X)	_	_	(52.5)	(19.1)
Net debt/equity (%)	(11.8)	(14.3)	(17.2)	(20.4)
Interest cover (X)	NM	NM	NM	NM
Inventory days	273.9	266.6	249.1	215.1
Receivable days	62.8	40.8	31.1	25.6
Days payable outstanding	142.4	105.5	81.3	77.5

## Growth & Margins (%)

	12/24	12/25E	12/26E	12/27E
Total revenue growth	(20.4)	3.7	3.6	13.5
EBITDA growth	(105.0)	59.0	499.0	228.3
EPS growth	(118.2)	(5.6)	44.8	186.2
DPS growth	NM	NM	NM	NM
Gross margin	67.5	68.5	69.0	68.1
EBIT margin	(5.2)	(6.1)	(5.0)	0.0

### Price Performance \_\_\_



8.9%

## Source: FactSet. Price as of 6 Jun 2025 close.

0.8%

(45.0)%

### Income Statement (\$ mn) \_

Rel. to the S&P 500

	12/24	12/25E	12/26E	12/27E
Total revenue	1,654.0	1,714.4	1,776.2	2,015.7
Cost of goods sold	(537.0)	(539.3)	(550.9)	(643.8)
SG&A	(120.0)	(136.0)	(142.0)	(159.0)
R&D	(1,083.0)	(1,143.0)	(1,172.0)	(1,212.0)
Other operating inc./(exp.)	_	-	-	-
EBITDA	(24.0)	(9.8)	39.3	128.9
Depreciation & amortization	(62.0)	(94.0)	(128.0)	(128.0)
EBIT	(86.0)	(103.8)	(88.7)	0.9
Net interest inc./(exp.)	_	-	-	-
Income/(loss) from associates	_	-	-	-
Pre-tax profit	(24.0)	(31.8)	(4.7)	87.9
Provision for taxes	(50.0)	(48.0)	(40.0)	(49.0)
Minority interest	_	_	-	-
Preferred dividends	_	_	-	-
Net inc. (pre-exceptionals)	(74.0)	(79.8)	(44.7)	38.9
Net inc. (post-exceptionals)	(3,090.0)	(404.8)	(300.7)	(165.1)
EPS (basic, pre-except) (\$)	(0.09)	(0.10)	(0.05)	0.05
EPS (diluted, pre-except) (\$)	(0.09)	(0.10)	(0.05)	0.05
EPS (ex-ESO exp., dil.) (\$)				
DPS (\$)	_	-	-	-
Div. payout ratio (%)	0.0	0.0	0.0	0.0
Wtd avg shares out. (basic) (mn)	808.4	814.5	818.5	822.5
Wtd avg shares out. (diluted) (mn)	808.4	826.3	838.0	846.0

## Balance Sheet (\$ mn)

	12/24	12/25E	12/26E	12/27E
Cash & cash equivalents	1,426.0	1,709.2	2,062.0	2,468.8
Accounts receivable	212.0	171.6	131.5	151.2
Inventory	415.0	372.7	379.1	379.9
Other current assets	121.0	122.0	122.0	122.0
Total current assets	2,174.0	2,375.5	2,694.5	3,121.8
Net PP&E	458.0	531.5	613.5	695.5
Net intangibles	9,809.0	9,365.0	8,965.0	8,617.0
Total investments	0.0	0.0	0.0	0.0
Other long-term assets	138.0	135.0	135.0	135.0
Total assets	12,579.0	12,407.0	12,408.0	12,569.3
Accounts payable	190.0	121.9	123.6	149.9
Short-term debt	_	_	_	-
Current lease liabilities	-	_	-	-
Other current liabilities	143.0	140.0	140.0	140.0
Total current liabilities	333.0	261.9	263.6	289.9
Long-term debt	_	_	_	_
Non-current lease liabilities	_	_	_	-
Other long-term liabilities	159.0	159.0	159.0	159.0
Total long-term liabilities	159.0	159.0	159.0	159.0
Total liabilities	492.0	420.9	422.6	448.9
Preferred shares	_	_	_	_
Total common equity	12,087.0	11,986.2	11,985.4	12,120.4
Minority interest	_	_	_	_
Total liabilities & equity	12,579.0	12,407.0	12,408.0	12,569.3
BVPS (\$)	14.95	14.72	14.64	14.74

### Cash Flow (\$ mn) \_\_\_

	12/24	12/25E	12/26E	12/27E
Net income	(3,090.0)	(404.8)	(300.7)	(165.1)
D&A add-back	62.0	94.0	128.0	128.0
Minority interest add-back	_	_	_	-
Net (inc)/dec working capital	112.0	33.5	35.5	5.8
Others	3,316.0	741.0	700.0	648.0
Cash flow from operations	400.0	463.7	562.8	616.8
Capital expenditures	(81.0)	(171.5)	(210.0)	(210.0)
Acquisitions	23.0	_	_	-
Divestitures	_	_	_	-
Others	(62.0)	(11.0)	_	-
Cash flow from investing	(120.0)	(182.5)	(210.0)	(210.0)
Dividends paid	_	_	_	-
Share issuance/(repurchase)	_	_	_	-
Inc/(dec) in debt	_	_	_	-
Others	(66.0)	2.0	_	-
Cash flow from financing	(66.0)	2.0	0.0	0.0
Total cash flow	214.0	283.2	352.8	406.8
Free cash flow	319.0	292.2	352.8	406.8
Free cash flow per share (basic) (\$)	0.39	0.36	0.43	0.49

Source: Company data, Goldman Sachs Research estimates.

for L1/L2 programs.

However, with respect to higher level ADAS and AV programs for consumer and commercial vehicles, while Mobileye has had some wins in the last few years (in particular with VW for both L2++/L3 ADAS and AVs), many OEMs that have been customers for Mobileye historically have announced plans for L2++/L3/L4 programs that are based on in-house and/or competitor designs. This includes Ford (in-house effort for L3, and management stated the company could license L4 technology from Tesla or Waymo), GM (in-house effort, and collaborating with Nvidia on Al), Honda (working with Renesas and Helm.ai) and Nissan (with Wayve). To be clear, some or all these OEMs could still work with Mobileye on certain programs or eventually choose to move to Mobileye more generally (as VW did with CARIAD), but we think OEM announcements over the last 12-18 months highlighting other plans suggests a lower opportunity set for Mobileye than we had previously expected.


Exhibit 1: Higher levels of autonomy (L2+ through L5) landscape

	Higher levels of autonomy (L2+ through L5) landscape - Select plans by OEM					
OEM	Partner(s)					
General Motors	In-house development for L3/L4; AI collaboration with NVDA					
Ford	For L3 the company plans to use in-house technology. For L4, Ford has commented that it is evaluating licensing					
Fold	from other companies, potentially Waymo or Tesla					
Tesla	In-house technology					
Rivian	Utilizing Nvidia as a chip provider; in-house software and system development					
Volkswagen	Mobileye					
Geely	Mobileye, and also in-house technology using Nvidia silicon					
Toyota	potential strategic agreement with Waymo for L4					
Honda	Renesas as chip provider and in-house development with contribution from Helm AI for advanced products					
Nissan	In house development with contribution from Wayve for advanced products					
Marubeni/Lyft	Mobileye to power robotaxis deployed by Marubeni on Lyft network, with launch in Dallas Texas					
VW/Uber	Uber to deploy Mobileye powered VW robotaxis in multiple markets					

Source: Company data, Data compiled by Goldman Sachs Global Investment Research

While Mobileye commented on its 2Q24 earnings call that it expected additional design wins by year-end 2024 with more to come in 2025 for SuperVision/Chauffeur, and also disclosed at its December 2024 investor day that five auto OEMs were in the due diligence and/or decision making phases for SuperVision/Chauffeur (Mobileye's L2++ and L3 products respectively), the last award announcement for these products was in January 2024 with VW. To be clear, we still expect Mobileye to get additional awards with SuperVison and Chauffeur, but if this occurs the timing would be later than we had expected and the lack of awards over the last 18 months coupled with OEM announcements highlighting other ADAS/AV tech plans suggests that the overall number of awards for Mobileye will be less than we expected. In addition, any new awards for SuperVision/Chauffeur even if they were to come this summer are unlikely to ramp to more material volumes until 2028 (based on typical product ramp times in the industry).

Exhibit 2: MBLY stock trading chart and key design win annoucements




Source: Company data, FactSet, Goldman Sachs Global Investment Research

### Weaker sales in China


Separately, Mobileye's revenue has declined in China. The percent of its revenue from China (based on the shipped-to location) declined from 31% in 2023 to 26% in 2024, implying a 33% decline in revenue. We attribute this to factors including tariffs, inventory adjustments, and lower market share. Geely for example has decreased the share of Mobileye SuperVision with its Zeekr vehicles (opting to use more of its in-house solution based on Nvidia silicon instead), and we think Mobileye faces competition from other merchant vendors including Horizon Robotics (covered by Allen Chang).

Exhibit 3: Mobileye revenue from shipments to China 2021-2024



Source: Company data

Exhibit 4: EyeQ shipments to China decreased meaningfully in 2024




Source: Company data

9 June 2025

### Estimates - Our estimates are about in line for 2025 but below for 2026/2027

Street estimates have come down over the last few years, with the consensus for 2026 non-GAAP EBITDA reduced by 85% since 1/31/2023. We attribute this to inventory adjustments, industry volumes/tariffs, and market share dynamics.


Exhibit 5: 2026 sales and EBITDA estimates have come down meaningfully since 2023



Source: FactSet

Our 2025 estimates are similar to consensus, but our estimates for 2026/2027 are below the Street. We do expect growth in 2026/2027 revenue/EPS as Mobileye begins to increase sales for AVs (with programs including VW and Uber/Lyft and Marubeni/Holon/Verne) but we expect a more measured build than consensus.

Exhibit 6: Our estimates are below the Street on the top and bottom line for CY26E-27E




EPS excludes SBC

Source: FactSet, Goldman Sachs Global Investment Research

## Valuation is full

We consider valuation to be full, with Mobileye trading near the high-end of its historical range on forward EBITDA.

Exhibit 7: Chipset providers Q5-Q8 EV/EBITDA multiple



Source: FactSet

## Price target and key risks

We downgrade MBLY shares to Neutral from Buy. We maintain our 2025/26/27 EPS estimates including SBC of -\$0.10/-\$0.05/\$0.05. We model EPS excluding SBC of \$0.27/\$0.30/\$0.40 respectively.

We maintain our 12-month price target of \$17, which is still based on 35X Q5-Q8 EBITDA ex. SBC. Key risks relate to: 1) the success it has (positively or negatively) with new design wins and if the company is able to secure more or less wins than we anticipate this could lead to more/less upside than our current expectations; 2) the rate of ADAS/AV penetration in the market with more penetration potentially driving more upside and less penetration potentially driving more downside, 3) more or less growth in auto production relative to our expectations could lead to more or less chip shipments from Mobileye than we expect, 4) Financials - lower or higher ASPs/margins, and 5) corporate actions.

## Disclosure Appendix

### Reg AC

We, Mark Delaney, CFA, Will Bryant and Aman Gupta, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

### **GS Factor Profile**

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

**Growth** is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

### M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

### Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

### **Disclosures**

The rating(s) for Mobileye Global Inc. is/are relative to the other companies in its/their coverage universe: Amphenol Corp., Aurora Innovation Inc., Belden Inc., BorgWarner Inc., Cerence Inc., ChargePoint Holdings, Flex, Ford Motor Co., General Motors Co., Gentex Corp., Innoviz Technologies, Jabil Circuit Inc., Keysight Technologies Inc., Lear Corp., Luminar Technologies Inc., Magna International Inc., Mobileye Global Inc., QuantumScape Corp., Rivian Automotive Inc., Sensata Technologies Holding, Symbotic Inc., TE Connectivity Plc, Tesla Inc., Vertiv Holdings, Visteon Corp.

### **Company-specific regulatory disclosures**

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies covered by Goldman Sachs Global Investment Research and referred to in this research.

Goldman Sachs beneficially owned 1% or more of common equity (excluding positions managed by affiliates and business units not required to be aggregated under US securities law) as of the second most recent month end: Mobileye Global Inc. (\$16.88)

Goldman Sachs has received compensation for investment banking services in the past 12 months: Mobileye Global Inc. (\$16.88)

Goldman Sachs expects to receive or intends to seek compensation for investment banking services in the next 3 months: Mobileye Global Inc. (\$16.88)

Goldman Sachs had an investment banking services client relationship during the past 12 months with: Mobileye Global Inc. (\$16.88)

Goldman Sachs had a non-investment banking securities-related services client relationship during the past 12 months with: Mobileye Global Inc. (\$16.88)

Goldman Sachs makes a market in the securities or derivatives thereof: Mobileye Global Inc. (\$16.88)

### Distribution of ratings/investment banking relationships


Goldman Sachs Investment Research global Equity coverage universe

	Rating Distribution		Investment Banking Relationships			
	Buy	Hold	Sell	Buy	Hold	Sell
Global	49%	34%	17%	63%	57%	42%

As of April 1, 2025, Goldman Sachs Global Investment Research had investment ratings on 3,016 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided

investment banking services within the previous twelve months.

### Price target and rating history chart(s)



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.

### Regulatory disclosures

### Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with subject company, public appearances and trading securities held by the analysts.

**Distribution of ratings:** See the distribution of ratings disclosure above. **Price chart:** See the price chart, with changes of ratings and price targets in prior periods, above, or, if electronic format or if with respect to multiple companies which are the subject of this report, on the Goldman Sachs website at <a href="https://www.gs.com/research/hedge.html">https://www.gs.com/research/hedge.html</a>.

### Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. Australia: Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. Brazil: Disclosure information in relation to CVM Resolution n. 20 is available at https://www.gs.com/worldwide/brazil/area/gir/index.html. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. Canada: This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. Hong Kong: Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. India: Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 951-A, Rational House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details can be found at this link: https://publishing.gs.com/disclosures/hedge.html - /general/equity. Japan: See below. Korea: This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. New Zealand: Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of

New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: <a href="https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html">https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html</a>. Russia: Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. Singapore: Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. Taiwan: This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. United Kingdom: Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by

**European Union and United Kingdom:** Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at <a href="https://www.gs.com/disclosures/europeanpolicy.html">https://www.gs.com/disclosures/europeanpolicy.html</a> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, The Investment Trusts Association, Japan, and Japan Investment Advisers Association. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

### Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.

**Total return potential** represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

**Coverage Universe:** A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at <a href="https://www.gs.com/research/hedge.html">https://www.gs.com/research/hedge.html</a>.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. Early-Stage Biotech (ES). An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company neither has a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. Rating Suspended (RS). Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. Coverage Suspended (CS). Goldman Sachs has suspended coverage of this company. Not Covered (NC). Goldman Sachs does not cover this company.

### Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

**European Economic Area:** GSI, authorised by the PRA and regulated by the FCA and the PRA, disseminates research in the following jurisdictions within the European Economic Area: the Grand Duchy of Luxembourg, Italy, the Kingdom of Belgium, the Kingdom of Denmark, the Kingdom of Norway, the Republic of Finland and the Republic of Ireland; GSI - Succursale de Paris (Paris branch) which is authorised by the French Autorité de contrôle prudentiel et de resolution ("ACPR") and regulated by the Autorité de contrôle prudentiel et de resolution and the Autorité des marches ("AMF") disseminates research in France; GSI - Succursal en España (Madrid branch) authorized in Spain by the Comisión Nacional del Mercado de Valores disseminates research in the Kingdom of Spain; GSI - Sweden Bankfilial (Stockholm branch) is authorized by the SFSA as a "third country branch" in accordance with Chapter 4, Section 4 of the Swedish Securities and Market Act (Sw. lag (2007:528) om värdepappersmarknaden) disseminates research in the Kingdom of Sweden; Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within

the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research in the Federal Republic of Germany and those jurisdictions within the European Economic Area where GSI is not authorised to disseminate research and additionally, GSBE, Copenhagen Branch filial af GSBE, Tyskland, supervised by the Danish Financial Authority disseminates research in the Kingdom of Denmark; GSBE - Succursal en España (Madrid branch) subject (to a limited extent) to local supervision by the Bank of Spain disseminates research in the Kingdom of Spain; GSBE - Succursale Italia (Milan branch) to the relevant applicable extent, subject to local supervision by the Bank of Italy (Banca d'Italia) and the Italian Companies and Exchange Commission (Commissione Nazionale per le Società e la Borsa "Consob") disseminates research in Italy; GSBE - Succursale de Paris (Paris branch), supervised by the AMF and by the ACPR disseminates research in France; and GSBE - Sweden Bankfillal (Stockholm branch), to a limited extent, subject to local supervision by the Swedish Financial Supervisory Authority (Finansinpektionen) disseminates research in the Kingdom of Sweden.

#### General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (<a href="https://www.sipc.org">https://www.sipc.org</a>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at <a href="https://www.theocc.com/about/publications/character-risks.jsp">https://www.theocc.com/about/publications/character-risks.jsp</a> and <a href="https://www.theocc.com/about/publications/character-risks.jsp</a> and <a href="https://www.theo

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to <a href="https://research.gs.com">https://research.gs.com</a>.

Disclosure information is also available at <a href="https://www.gs.com/research/hedge.html">https://www.gs.com/research/hedge.html</a> or from Research Compliance, 200 West Street, New York, NY 10282.

### © 2025 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.